Skip to main content

A Humanized Monoclonal Anti-Claudin1 Antibody (anti-CLDN1 mAb) for Treatment of Hepatocellular Carcinoma (HCC)

Project description

New immunotherapy targets cancerous cells that are immune to current treatment

Liver fibrosis is a scarring process resulting from the liver's response to chronic injury or inflammation. It is caused by viruses, diseases, and alcoholism. Over time, it can lead to cirrhosis, a disruption in the organisation of the functional units of the liver that can eventually impede blood flow to the liver. Fibrosis and cirrhosis are also linked to the development of an aggressive and lethal form of liver cancer. The cancer is characterised by emergence of drug-resistant cell populations in response to the only systemic treatment currently available. Even worse, persistent treatment seems to speed tumour progression. HEPCAN is targeting those drug-resistant cell populations through the development of powerful monoclonal antibodies designed to decimate the resistors.

Host institution

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Net EU contribution
€ 150 000,00
Address
Rue De Tolbiac 101
75654 Paris
France

See on map

Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Other funding
No data

Beneficiaries (1)

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
Net EU contribution
€ 150 000,00
Address
Rue De Tolbiac 101
75654 Paris

See on map

Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Other funding
No data